DRG Epidemiology's coverage of type 1 diabetes comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of type 1 diabetes for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
DRG Epidemiology's type 1 diabetes forecast will answer the following questions:
Of all people with type 1 diabetes, how many in each major mature pharmaceutical market are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of type 1 diabetes over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
DRG Epidemiology provides at least ten years of forecast data for the following type 1 diabetes patient populations:
Diagnosed Prevalence of Type 1 Diabetes per 1,000 People of All Ages in 2020 and 2040ttttttttt
Relative Sizes of the Factors Contributing to the Trend in Diagnosed Prevalent Cases of Type 1 Diabetes over the Next 20 Yearsttttttttt
Number of Additional Diagnosed Prevalent Cases of Type 1 Diabetes in 2040 in the Countries Under Study due to Trends in Risk or Survival
Epidemiology Data
Methods
Diagnosed Incident Cases of Type 1 Diabetes
Diagnosed Prevalent Cases of Type 1 Diabetes
Diagnosed Drug-Treated Prevalent Cases
Lifetime DALYs Gained
Reference Materials
Literature Review
Studies Included in the Analysis of Type 1 Diabetes
Studies Excluded from the Analysis of Type 1 Diabetes
Risk/Protective Factors
Risk/Protective Factors for Type 1 Diabetes
Bibliography
Glossary
Brynna Izquierdo, M.P.H.
Brynna Izquierdo, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Prior to joining DRG, she held various research assistant positions conducting secondary data analyses in the fields of psycho-oncology and chronic disease. She earned her M.P.H. in epidemiology and B.S. in public health from Temple University in Philadelphia.
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.
